Spots Global Cancer Trial Database for Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
Official Title: Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
Study ID: NCT00776867
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to test whether perifosine- a drug that inhibits the protein AKT, and has had some success in the treatment of adult cancers- is safe and effective in treating cancer. The investigators want to find out what effects, good and/or bad, it has on the patient and the cancer. The investigators are testing different dose schedules of perifosine and the patient will be asked to partake in one of the dose schedules.
Detailed Description:
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Contact Details
Name: Ira Dunkel, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
